273 related articles for article (PubMed ID: 20823411)
1. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
2. Small tumors, intermediate models, big hopes.
Siu LL
J Clin Oncol; 2010 Oct; 28(29):4407-9. PubMed ID: 20823413
[No Abstract] [Full Text] [Related]
3. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Buck E; Eyzaguirre A; Brown E; Petti F; McCormack S; Haley JD; Iwata KK; Gibson NW; Griffin G
Mol Cancer Ther; 2006 Nov; 5(11):2676-84. PubMed ID: 17121914
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Schmid K; Bago-Horvath Z; Berger W; Haitel A; Cejka D; Werzowa J; Filipits M; Herberger B; Hayden H; Sieghart W
Br J Cancer; 2010 Aug; 103(5):622-8. PubMed ID: 20683448
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
9. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
[TBL] [Abstract][Full Text] [Related]
10. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Allen E; Walters IB; Hanahan D
Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatment combinations: integrating therapy into clinical practice.
Wong ST
Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S9-S14. PubMed ID: 19923318
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
Hobday TJ; Qin R; Reidy-Lagunes D; Moore MJ; Strosberg J; Kaubisch A; Shah M; Kindler HL; Lenz HJ; Chen H; Erlichman C
J Clin Oncol; 2015 May; 33(14):1551-6. PubMed ID: 25488966
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
Chang Q; Chen E; Hedley DW
Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
[TBL] [Abstract][Full Text] [Related]
15. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
17. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.
Xie X; Ghadimi MP; Young ED; Belousov R; Zhu QS; Liu J; Lopez G; Colombo C; Peng T; Reynoso D; Hornick JL; Lazar AJ; Lev D
Clin Cancer Res; 2011 Sep; 17(18):5901-12. PubMed ID: 21821699
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Sloss CM; Wang F; Liu R; Xia L; Houston M; Ljungman D; Palladino MA; Cusack JC
Clin Cancer Res; 2008 Aug; 14(16):5116-23. PubMed ID: 18698029
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Buck E; Eyzaguirre A; Haley JD; Gibson NW; Cagnoni P; Iwata KK
Mol Cancer Ther; 2006 Aug; 5(8):2051-9. PubMed ID: 16928826
[TBL] [Abstract][Full Text] [Related]
20. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
